Prime Medicine received FDA clearance for its IND application for PM647, an investigational in vivo Prime Editor therapy for AATD. The clearance allows U.S. clinical studies to begin, targeting the PiZZ genotype carried by ~100,000 people. Initial clinical data are expected in 2027.